CompletedNot Applicable

Ditan Acute tReatments: Effectiveness and Tolerability (DART)

Italy100 participantsStarted 2023-06-15

Plain-language summary

The purpose of this prospective and multicentric study is to evaluate the effectiveness and tolerability of lasmiditan as acute migraine treatment in a cohort of episodic or chronic migraine patients.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the 3rd edition of the International Classification of Headache Disorder (ICHD-III). At least 3 MMDs * Good compliance to study procedures * Availability of headache diary at least of the preceding months before enrollment Exclusion Criteria: * Subjects with contraindications for use of ditans; * Concomitant diagnosis of medical diseases and/or comorbidities that, in the Investigator's opinion might interfere with study assessments; * medical comorbidities that could interfere with study results; * Pregnancy and breastfeeding.

What they're measuring

Headache pain freedom at 2 hours post dose during the first attack

Timeframe: 2 hours post-dose

Occurrence of treatment-emergent adverse events

Timeframe: 12 weeks

Trial details

NCT IDNCT05903040

SponsorUniversity of Florence

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-06-01

View on ClinicalTrials.gov More Migraine trials